v3.8.0.1
Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
NET REVENUE        
Clinical testing $ 56,186 $ 55,739 $ 172,668 $ 166,674
Pharma Services 6,866 5,022 18,150 16,919
Total Revenue 63,052 60,761 190,818 183,593
COST OF REVENUE 34,242 33,416 103,634 100,471
GROSS PROFIT 28,810 27,345 87,184 83,122
Operating expenses:        
General and administrative 23,267 19,025 66,743 55,810
Research and development 1,270 967 3,080 3,719
Sales and marketing 6,577 5,958 18,466 18,084
Loss on sale of Path Logic 1,058   1,058  
Total operating expenses 32,172 25,950 89,347 77,613
INCOME (LOSS) FROM OPERATIONS (3,362) 1,395 (2,163) 5,509
Interest expense, net 1,398 1,468 4,173 4,509
Income (loss) before taxes (4,760) (73) (6,336) 1,000
Income tax (benefit) expense 340 (6) (539) 500
NET INCOME (LOSS) (5,100) (67) (5,797) 500
Deemed dividends on preferred stock 912 1,840 2,734 5,520
Amortization of preferred stock beneficial conversion feature 1,739 3,727 5,122 11,180
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS $ (7,751) $ (5,634) $ (13,653) $ (16,200)
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS        
Basic $ (0.10) $ (0.07) $ (0.17) $ (0.21)
Diluted $ (0.10) $ (0.07) $ (0.17) $ (0.21)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:        
Basic 79,617 78,145 79,208 77,224
Diluted 79,617 78,145 79,208 77,224

Source